IHT is a European business group of Spanish origin dedicated to the development, manufacturing, and commercialization of medical devices. Since its founding, the company has been characterized by the continuous development of new business areas, driven by its commitment to ongoing investment in research and development.
Chronology
1980
Aniceto López founded Iberhospitex S.A. (IHT) in Barcelona for the development and production of single-use fabrics.
1985
The company’s headquarters was relocated to Lliçà de Vall, Barcelona, to a facility of over 4,000 m² dedicated to production and development.
1990
Foundation of IHT Medical S.A., a company dedicated to the import and commercialization of medical devices.
1993
Foundation of IHT Clinical, a French subsidiary dedicated to the commercialization of IHT products in the French market.
1998
IHT launches its first line of products for interventional cardiology, becoming one of the pioneering European companies in this specialty.
2003
Expansion of logistics and processing facilities.
2010
Inauguration of a new facility with over 6,000 m² dedicated to the development and production of products for the hospital division.
2015
Foundation of IHT Polska, a subsidiary dedicated to the commercialization of IHT products in Poland.
2017
First FDA registrations for the company and development of a range of biomaterials.
2020
Foundation of subsidiaries in Asia and Latin America to support international expansion.
2022
IHT launches its first range of drug-eluting dressings, thanks to investments in the development of proprietary biomaterials.
0
Years
Dedicated to medical devices
0
m/2
in production
0
Centers
of operations
0
Products
developed
Company history
Founded by Aniceto López in the early 1980s, IHT began its operations with the development of single-use textile materials for surgical protection.
In a short time, the company expanded its activities to include single-use drainage systems and wound dressings, becoming a pioneer in the development and introduction of several therapies at both national and European levels.
By the mid-1990s, IHT broadened its scope by developing a complete line of devices for interventional cardiology in just four years.
«Desde su fundación,IHT has committed to reinvesting profits.IHT has invested in Research & Development and reinvested profits as key drivers for the development of all its business lines.
Innovation
Devices
IHT has over 40 years of experience in the development and production of medical devices and more than 20 years of experience in interventional cardiology.
IHT works with a wide range of materials and equipment for the research, development, and manufacturing of new devices. The company's focus is on developing new products and technologies for the treatment of diseases.
Biomaterials
IHT has a specialized unit dedicated to the research and development of biomaterials, which are designed for specific applications and can provide significant advantages in terms of usability and outcomes.
Over the past 10 years, highly complex materials have been developed, such as substances capable of controlling drug release, and hydrogels, among others.
Adhesion
Adhesive laminating is one of the most critical technologies for the company.
IHT has over 35 years of experience in the field of adhesion, mastering various adhesive technologies.
Converting
Within the wound care divisions, mass production and robustness are essential.
One of IHT's strategic focuses in continuous improvement is the optimization of systems such as cutting, composition, and vision-based inspection.
Throughout its more than 30 years in the industry, the company has developed numerous processes in collaboration with leading companies in the sector.
Technology Transfer
Since its founding, IHT has worked closely with medical professionals in the development of new products, making this collaboration one of its main drivers of innovation.
On the other hand, IHT has a dedicated team solely focused on designing and conducting clinical studies that evaluate and validate our products in real-world situations, allowing for continuous improvement and optimization.
Automation
Improving product quality, increasing production capacity, and enhancing industrial costs have been constant objectives for the company since its founding.
Therefore, the development of automated systems is one of the main drivers for cost optimization.
Commitment
Experience: 40 years in the medical device business, with over 20 years in coronary intervention.
Committed to Quality and the Environment: IHT demonstrates its commitment to quality and the environment by adhering to ISO 9001, 13485, and 14001 standards.
Para poder acceder a este contenido, necesitamos verificar que usted es un profesional médico. Para ello, rellene el formulario en Contacto y crearemos un usuario para usted.
